Biotech Growth / Late Growth Stage CEO Forum - 2020 Programme
The prevailing theme during this CEO Forum is survivability and thrivability during COVID-19.
A unique, powerful and valuable space for the candid sharing of experience between 25 of the sector’s emerging and innovative post-series A Biotech executives. Like-minded Executives are joined by 2-3 appropriate and value-matched industry stakeholders and partners to provide expertise, experience and best practice on strategic areas of focus. Case studies will also be delivered by a number of executives in the room who have enjoyed success or navigated key challenges in their pursuit of company growth.
A pre-registration only, exclusive hollow square forum where all participants are active discussants. This CEO forum is delivered in a virtual setting via Zoom.
Attendance is FREE, however executives must satisfy a number of key criteria points outlined during registration.
Executive qualifier: Company executives must be post-series A and from a US-based therapeutic-indication Biotech company
Date: Wednesday, 7th October 2020
Timings: 14:00 - 16:20 EDT / 11:00 - 13:20 PDT
Co-Hosted by:
14.00 - Chairman – Neil Darkes, Co-CEO, LSX Leaders
14.00 - Using data and machine learning for better R&D decision making
Current clinical environments demand that organizations move faster, find new efficiencies, and drive better patient outcomes. The most successful sponsors are learning how to incorporate data, AI and expertise in order to implement “Decision Intelligence” into their drug development process. Join this session to learn how to modernize and strategize from molecule to market.
Michael Kardas, PharmD, Vice President and Global Head, Strategic Drug Development, IQVIA
Lucas Glass, Global Leader, Analytics Center of Excellence, IQVIA
14.20 – CEO case study - finance and capital raising during COVID-19 - securing that game-changing financing - $100m oversubscribed Series B
Anthony Johnson, CEO, Goldfinch Bio
Dr. Tony Johnson joined Goldfinch Bio as president and chief executive officer in 2017. He brings 25 years of academic, industry and venture experience including several years in R&D senior leadership roles.
Prior to Goldfinch Bio, Tony was head of early clinical development and chief medical officer of the Innovative Medicines and Early Development Biotech Unit at AstraZeneca, and a Fellow at Homerton College, Cambridge, UK. This role was preceded by experience as a venture partner at OrbiMed Advisors and industry positions as vice president, discovery medicine and clinical pharmacology with Bristol-Myers Squibb, vice president, discovery medicine at GlaxoSmithKline and founding director of the GlaxoWelcome Medicines Research Unit. He was a tenured academic at the University of Queensland, Australia prior to his industry experience.
14.40 – Fireside chat case study - Goodwin and iTeos Therapeutics - anatomy of an oversubscribed $200m IPO with iTeos Therapeutics
Danielle Lauzon is a partner in Goodwin’s Technology Companies & Life Sciences group and leader of the firm’s Business Law Department in Boston. From 2007 through 2012, Ms. Lauzon was recognized as Massachusetts Super Lawyer “Rising Star” for her work representing private and public companies on general corporate and securities law and mergers and acquisitions. Ms. Lauzon also represents issuers in connection with the public offering and private placement of equity securities, and has represented companies as well as venture capital and private equity firms in numerous venture capital financings and recapitalizations.
Ms. Lauzon acts as co-chair of Goodwin’s PropSci practice which is focused on supporting the intersection of real estate and life sciences. Through our industry and practice area connectivity, and leveraging our existing reputation as leaders in the real estate and life sciences spaces, Goodwin provides clients integrated and innovative services that adapt along with their needs.
Michel has served as our Chief Executive Officer and a director since our inception. He previously served as a director at Ludwig Cancer Research from December 2010 to March 2012. Prior to that, Michel worked in various scientific and business development roles at Ogeda (f/k/a Euroscreen). Michel holds a degree in biochemistry and a Ph.D. in Biochemistry from Université Catholique de Louvain and a business certificate from Solvay Business School.
15.10 – Fireside chat case study - Cello Health BioConsulting and Nodthera - company growth and strategic positioning
Ed is Executive Chairman of Cello Health BioConsulting (CHBC), previously Defined Health, after having led the sale of Defined Health to Cello Health in 2017. CHBC is a leading strategic business development advisory firm serving senior executives in pharma, biotech and investment sectors at clients based in the US, Europe, Japan/Asia and Israel. Ed possesses a vast knowledge of the pharmaceutical and biotechnology industry accumulated over Defined Health’s 25+ years of consultancy to pharma, biotech, specialty pharma and investors. From this breadth and depth of experience, he provides guidance to CHBC’s senior project leadership who work with clients across multiple therapeutic areas.
Adam previously held the position of global head of business development at Sanofi Genzyme, where he led BD activities across each of Sanofi’s specialty care therapeutic areas, including immunology, neurology, oncology, rare diseases and rare blood disorders. Adam was also head of R&D strategy and chair of the internal governance body that oversaw the review, prioritization and execution of all external R&D investments at Sanofi. Prior to Sanofi, Adam held roles of increasing responsibility at Johnson & Johnson, including as site head of the company’s California Innovation Center, where he catalyzed early stage innovation across J&J’s pharmaceuticals businesses. Adam began his career as a research scientist at H. Lundbeck A/S. He holds a Ph.D. in neuropharmacology from the University of Nottingham, UK.
15.40 – General Discussion
Discussion to include but not limited to:
Ed is Executive Chairman of Cello Health BioConsulting (CHBC), previously Defined Health, after having led the sale of Defined Health to Cello Health in 2017. CHBC is a leading strategic business development advisory firm serving senior executives in pharma, biotech and investment sectors at clients based in the US, Europe, Japan/Asia and Israel. Ed possesses a vast knowledge of the pharmaceutical and biotechnology industry accumulated over Defined Health’s 25+ years of consultancy to pharma, biotech, specialty pharma and investors. From this breadth and depth of experience, he provides guidance to CHBC’s senior project leadership who work with clients across multiple therapeutic areas.
16.20 – Forum Close
Current CEO participants include:
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
ImReg Pharmaceuticals |  |
 |
|
 |
|
 |
 |
 |
 |
|
 |
 |
|
 |
 |
 |
|
 |
|
|
.jpg?width=343&name=TREOS_logo_v4_horiz_30%20(1).jpg){kind=logo} |
Vigil Neuroscience |  |
For enquiries contact:
Matt Pullan, SVP, Business Development
matt@lsxleaders.com
